PROTO, CLAUDIA
PROTO, CLAUDIA
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports.
2012-01-01 Franchina, Tindara; Adamo, Barbara; Ricciardi, GIUSEPPINA ROSARIA; Caristi, Nicola; Agostino, RITA MARIA; Proto, Claudia; Adamo, Vincenzo
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: a case report.
2011-01-01 Franchina, Tindara; Proto, Claudia; Noto, L; Chiofalo, G; Ferraro, G; Picciotto, Maria; Adamo, V.
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations.
2011-01-01 Franchina, Tindara; Caristi, Nicola; Proto, Claudia; Chiofalo, G; Toscano, G; Ricciardi, GIUSEPPINA ROSARIA; Colonese, F; Caccamo, Daniela; Ientile, Riccardo; Adamo, Vincenzo
Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer
2012-01-01 Franchina, Tindara; Amodeo, V; Proto, Claudia; Bronte, G; Savio, G; Russo, Alessandro; Toscano, G; Russo, A; Adamo, Vincenzo
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution.
2012-01-01 Franchina, Tindara; Bronte, G; Savio, G; Ferraro, Giuseppa; Proto, Claudia; Berenato, Rosa; Noto, Laura; Chiofalo, G; Russo, A; Adamo, Vincenzo
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ?
2010-01-01 Franchina, Tindara; Scimone, Andrea; Ferraro, Giuseppa; Garipoli, Claudia; Zanghi', Mariangela; Berenato, Rosa; Briguglio, Roberta; Noto, Laura; Proto, Claudia; Adamo, Vincenzo
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience.
2011-01-01 Caristi, Nicola; Franchina, Tindara; Proto, Claudia; Chiofalo, G; Toscano, G; Scimone, A; Zanghi', Mariangela; Berenato, R; Briguglio, Roberta; Denaro, Nerina; Noto, Laura; Adamo, Vincenzo
Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient
2014-01-01 Ricciardi, Giuseppina Rosaria Rita; Proto, Claudia; Ferraro, Giuseppa; Adamo, Vincenzo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. | 1-gen-2012 | Franchina, Tindara; Adamo, Barbara; Ricciardi, GIUSEPPINA ROSARIA; Caristi, Nicola; Agostino, RITA MARIA; Proto, Claudia; Adamo, Vincenzo | |
| Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: a case report. | 1-gen-2011 | Franchina, Tindara; Proto, Claudia; Noto, L; Chiofalo, G; Ferraro, G; Picciotto, Maria; Adamo, V. | |
| Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. | 1-gen-2011 | Franchina, Tindara; Caristi, Nicola; Proto, Claudia; Chiofalo, G; Toscano, G; Ricciardi, GIUSEPPINA ROSARIA; Colonese, F; Caccamo, Daniela; Ientile, Riccardo; Adamo, Vincenzo | |
| Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer | 1-gen-2012 | Franchina, Tindara; Amodeo, V; Proto, Claudia; Bronte, G; Savio, G; Russo, Alessandro; Toscano, G; Russo, A; Adamo, Vincenzo | |
| New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. | 1-gen-2012 | Franchina, Tindara; Bronte, G; Savio, G; Ferraro, Giuseppa; Proto, Claudia; Berenato, Rosa; Noto, Laura; Chiofalo, G; Russo, A; Adamo, Vincenzo | |
| Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? | 1-gen-2010 | Franchina, Tindara; Scimone, Andrea; Ferraro, Giuseppa; Garipoli, Claudia; Zanghi', Mariangela; Berenato, Rosa; Briguglio, Roberta; Noto, Laura; Proto, Claudia; Adamo, Vincenzo | |
| Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. | 1-gen-2011 | Caristi, Nicola; Franchina, Tindara; Proto, Claudia; Chiofalo, G; Toscano, G; Scimone, A; Zanghi', Mariangela; Berenato, R; Briguglio, Roberta; Denaro, Nerina; Noto, Laura; Adamo, Vincenzo | |
| Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient | 1-gen-2014 | Ricciardi, Giuseppina Rosaria Rita; Proto, Claudia; Ferraro, Giuseppa; Adamo, Vincenzo |